496 related articles for article (PubMed ID: 22752507)
1. Reduction of circulating regulatory T cells by intravenous high-dose interferon alfa-2b treatment in melanoma patients.
Mozzillo N; Ascierto P
Clin Exp Metastasis; 2012 Oct; 29(7):801-5. PubMed ID: 22752507
[TBL] [Abstract][Full Text] [Related]
2. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment.
Ascierto PA; Napolitano M; Celentano E; Simeone E; Gentilcore G; Daponte A; Capone M; Caracò C; Calemma R; Beneduce G; Cerrone M; De Rosa V; Palmieri G; Castello G; Kirkwood JM; Marincola FM; Mozzillo N
J Transl Med; 2010 Aug; 8():76. PubMed ID: 20712892
[TBL] [Abstract][Full Text] [Related]
3. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma.
Eggermont AM; Suciu S; Testori A; Santinami M; Kruit WH; Marsden J; Punt CJ; Salès F; Dummer R; Robert C; Schadendorf D; Patel PM; de Schaetzen G; Spatz A; Keilholz U
J Clin Oncol; 2012 Nov; 30(31):3810-8. PubMed ID: 23008300
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of pegylated interferon-alpha-2b as an adjuvant therapy in Japanese patients with malignant melanoma.
Yamazaki N; Uhara H; Wada H; Matsuda K; Yamamoto K; Shimamoto T; Kiyohara Y
J Dermatol; 2016 Oct; 43(10):1146-1153. PubMed ID: 27087489
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.
Grob JJ; Jouary T; Dréno B; Asselineau J; Gutzmer R; Hauschild A; Leccia MT; Landthaler M; Garbe C; Sassolas B; Herbst RA; Guillot B; Chene G; Pehamberger H
Eur J Cancer; 2013 Jan; 49(1):166-74. PubMed ID: 22975216
[TBL] [Abstract][Full Text] [Related]
6. Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874].
Chiarion-Sileni V; Del Bianco P; Romanini A; Guida M; Paccagnella A; Dalla Palma M; Naglieri E; Ridolfi R; Silvestri B; Michiara M; De Salvo GL
BMC Cancer; 2006 Feb; 6():44. PubMed ID: 16504154
[TBL] [Abstract][Full Text] [Related]
7. Regulatory T cells and other lymphocyte subpopulations in patients with melanoma developing interferon-induced thyroiditis during high-dose interferon-α2b treatment.
Soldevila B; Alonso N; Martínez-Arconada MJ; Granada ML; Boada A; Vallejos V; Fraile M; Fernández-Sanmartín MA; Pujol-Borrell R; Puig-Domingo M; Sanmartí A; Martínez-Cáceres EM
Clin Endocrinol (Oxf); 2013 Apr; 78(4):621-8. PubMed ID: 22957689
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial.
Eggermont AMM; Rutkowski P; Dutriaux C; Hofman-Wellenhof R; Dziewulski P; Marples M; Grange F; Lok C; Pennachioli E; Robert C; van Akkooi ACJ; Bastholt L; Minisini A; Marshall E; Salès F; Grob JJ; Bechter O; Schadendorf D; Marreaud S; Kicinski M; Suciu S; Testori AAE
Eur J Cancer; 2020 Jul; 133():94-103. PubMed ID: 32470710
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses.
Moschos SJ; Edington HD; Land SR; Rao UN; Jukic D; Shipe-Spotloe J; Kirkwood JM
J Clin Oncol; 2006 Jul; 24(19):3164-71. PubMed ID: 16809739
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant interferon therapy for malignant melanoma: the debate.
Zhou Q; Zhang XS
Chin J Cancer; 2010 Nov; 29(11):907-13. PubMed ID: 20979689
[TBL] [Abstract][Full Text] [Related]
11. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial.
Hansson J; Aamdal S; Bastholt L; Brandberg Y; Hernberg M; Nilsson B; Stierner U; von der Maase H;
Lancet Oncol; 2011 Feb; 12(2):144-52. PubMed ID: 21256809
[TBL] [Abstract][Full Text] [Related]
12. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.
Eggermont AM; Suciu S; Santinami M; Testori A; Kruit WH; Marsden J; Punt CJ; Salès F; Gore M; MacKie R; Kusic Z; Dummer R; Hauschild A; Musat E; Spatz A; Keilholz U;
Lancet; 2008 Jul; 372(9633):117-126. PubMed ID: 18620949
[TBL] [Abstract][Full Text] [Related]
13. The efficacy and safety of adjuvant interferon-alfa therapy in the evolving treatment landscape for resected high-risk melanoma.
Trinh VA; Zobniw C; Hwu WJ
Expert Opin Drug Saf; 2017 Aug; 16(8):933-940. PubMed ID: 28627943
[TBL] [Abstract][Full Text] [Related]
14. Analysis of surrogate gene expression markers in peripheral blood of melanoma patients to predict treatment outcome of adjuvant pegylated interferon alpha 2b (EORTC 18991 side study).
Busse A; Rapion J; Fusi A; Suciu S; Nonnenmacher A; Santinami M; Kruit WH; Testori A; Punt CJ; Dalgleish AG; Spatz A; Eggermont AM; Keilholz U
Cancer Immunol Immunother; 2013 Jul; 62(7):1223-33. PubMed ID: 23624802
[TBL] [Abstract][Full Text] [Related]
15. Preferences of German melanoma patients for interferon (IFN) α-2b toxicities (the DeCOG "GERMELATOX survey") versus melanoma recurrence to quantify patients' relative values for adjuvant therapy.
Kaehler KC; Blome C; Forschner A; Gutzmer R; Haalck T; Heinzerling L; Kornek T; Livingstone E; Loquai C; Maul LV; Lang BM; Schadendorf D; Stade B; Terheyden P; Utikal J; Wagner T; Hauschild A; Garbe C; Augustin M
Medicine (Baltimore); 2016 Nov; 95(46):e5375. PubMed ID: 27861370
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma: a phase III randomized controlled trial of health-related quality of life and symptoms by the European Organisation for Research and Treatment of Cancer Melanoma Group.
Bottomley A; Coens C; Suciu S; Santinami M; Kruit W; Testori A; Marsden J; Punt C; Salès F; Gore M; Mackie R; Kusic Z; Dummer R; Patel P; Schadendorf D; Spatz A; Keilholz U; Eggermont A
J Clin Oncol; 2009 Jun; 27(18):2916-23. PubMed ID: 19433686
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma.
Tarhini AA; Cherian J; Moschos SJ; Tawbi HA; Shuai Y; Gooding WE; Sander C; Kirkwood JM
J Clin Oncol; 2012 Jan; 30(3):322-8. PubMed ID: 22184371
[TBL] [Abstract][Full Text] [Related]
18. Prospective randomized multicenter adjuvant dermatologic cooperative oncology group trial of low-dose interferon alfa-2b with or without a modified high-dose interferon alfa-2b induction phase in patients with lymph node-negative melanoma.
Hauschild A; Weichenthal M; Rass K; Linse R; Ulrich J; Stadler R; Volkenandt M; Grabbe S; Proske U; Schadendorf D; Brockmeyer N; Vogt T; Rompel R; Kaufmann R; Kaatz M; Näher H; Mohr P; Eigentler T; Livingstone E; Garbe C
J Clin Oncol; 2009 Jul; 27(21):3496-502. PubMed ID: 19433681
[TBL] [Abstract][Full Text] [Related]
19. Phase III Randomized Study of 4 Weeks of High-Dose Interferon-α-2b in Stage T2bNO, T3a-bNO, T4a-bNO, and T1-4N1a-2a (microscopic) Melanoma: A Trial of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network Cancer Research Group (E1697).
Agarwala SS; Lee SJ; Yip W; Rao UN; Tarhini AA; Cohen GI; Reintgen DS; Evans TL; Brell JM; Albertini MR; Atkins MB; Dakhil SR; Conry RM; Sosman JA; Flaherty LE; Sondak VK; Carson WE; Smylie MG; Pappo AS; Kefford RF; Kirkwood JM
J Clin Oncol; 2017 Mar; 35(8):885-892. PubMed ID: 28135150
[TBL] [Abstract][Full Text] [Related]
20. Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial.
Eggermont AM; Suciu S; MacKie R; Ruka W; Testori A; Kruit W; Punt CJ; Delauney M; Sales F; Groenewegen G; Ruiter DJ; Jagiello I; Stoitchkov K; Keilholz U; Lienard D;
Lancet; 2005 Oct; 366(9492):1189-96. PubMed ID: 16198768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
